Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novavax, Inc. stock logo
NVAX
Novavax
$7.98
-3.6%
$7.66
$5.01
$15.22
$1.34B2.686.75 million shs7.15 million shs
WalkMe Ltd. stock logo
WKME
WalkMe
$13.95
$13.90
$7.60
$14.09
$1.21B0.16438,095 shsN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+1.01%-15.38%+14.99%-35.07%
WalkMe Ltd. stock logo
WKME
WalkMe
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novavax, Inc. stock logo
NVAX
Novavax
$7.98
-3.6%
$7.66
$5.01
$15.22
$1.34B2.686.75 million shs7.15 million shs
WalkMe Ltd. stock logo
WKME
WalkMe
$13.95
$13.90
$7.60
$14.09
$1.21B0.16438,095 shsN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+1.01%-15.38%+14.99%-35.07%
WalkMe Ltd. stock logo
WKME
WalkMe
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Novavax, Inc. stock logo
NVAX
Novavax
2.13
Hold$14.2979.02% Upside
WalkMe Ltd. stock logo
WKME
WalkMe
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NVAX and WKME Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2025
Novavax, Inc. stock logo
NVAX
Novavax
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$10.00
8/20/2025
Novavax, Inc. stock logo
NVAX
Novavax
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutralUnderperform$9.00 ➝ $7.00
7/22/2025
Novavax, Inc. stock logo
NVAX
Novavax
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$10.00 ➝ $9.00
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell$6.00
(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.90N/AN/A($3.89) per share-2.05
WalkMe Ltd. stock logo
WKME
WalkMe
$266.95M4.53N/AN/A$3.00 per share4.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.283.5099.750.1139.20%-142.33%28.65%11/11/2025 (Estimated)
WalkMe Ltd. stock logo
WKME
WalkMe
-$59.14M-$0.44N/AN/A-16.55%-9.60%-5.43%N/A

Latest NVAX and WKME Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
WalkMe Ltd. stock logo
WKME
WalkMe
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Novavax, Inc. stock logo
NVAX
Novavax
5.93
2.36
2.34
WalkMe Ltd. stock logo
WKME
WalkMe
N/A
2.04
2.04

Institutional Ownership

CompanyInstitutional Ownership
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
WalkMe Ltd. stock logo
WKME
WalkMe
70.91%

Insider Ownership

CompanyInsider Ownership
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
WalkMe Ltd. stock logo
WKME
WalkMe
27.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990162.42 million160.80 millionOptionable
WalkMe Ltd. stock logo
WKME
WalkMe
1,21086.78 million62.86 millionOptionable

Recent News About These Companies

3 Global Stocks to Diversify Your Portfolio
WalkMe Inc.: SAP Completes Acquisition of WalkMe
SAP Closes Acquisition Of WalkMe
Where are the Opportunities in (WKME)
SAP Completes Acquisition of WalkMe
(WKME) Investment Report
Needham Reaffirms Their Hold Rating on WalkMe (WKME)
WalkMe Ltd Ordinary Shares
Trading (WKME) With Integrated Risk Controls
WalkMe Celebrates Winners of Annual Realizer Awards

New MarketBeat Followers Over Time

Media Sentiment Over Time

Novavax stock logo

Novavax NASDAQ:NVAX

$7.98 -0.30 (-3.62%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$7.98 0.00 (-0.01%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

WalkMe stock logo

WalkMe NASDAQ:WKME

WalkMe Ltd. provides cloud-based digital adaption platform and associated professional services in the United States and internationally. The company's AI-driven digital adoption platform helps companies to effectively navigate change brought by technology, which stack, identifies, and delivers the personalized guidance and automation. In addition, the company WalkMe's platform is delivered via web, desktop or mobile and pre-packaged to support the key workflows. The company was formerly known as Make Tutorial Ltd. and changed its name to WalkMe Ltd. in March 2012. WalkMe Ltd. was incorporated in 2011 and is headquartered in Tel Aviv, Israel.